Evaluating cepharanthine analogues as natural drugs against SARS‐CoV‐2
-
- Atsushi Hijikata
- Faculty of Bioscience Nagahama Institute of Bio‐Science and Technology Japan
-
- Clara Shionyu‐Mitsuyama
- Faculty of Bioscience Nagahama Institute of Bio‐Science and Technology Japan
-
- Setsu Nakae
- Faculty of Bioscience Nagahama Institute of Bio‐Science and Technology Japan
-
- Masafumi Shionyu
- Faculty of Bioscience Nagahama Institute of Bio‐Science and Technology Japan
-
- Motonori Ota
- Department of Complex Systems Science Graduate School of Informatics Nagoya University Japan
-
- Shigehiko Kanaya
- Computational Biology Laboratory Division of Information Science Graduate School of Science and Technology Nara Institute of Science and Technology (NAIST) Ikoma Japan
-
- Takatsugu Hirokawa
- Division of Biomedical Science Faculty of Medicine University of Tsukuba Japan
-
- Shogo Nakajima
- Department of Virology II National Institute of Infectious Diseases Shinjuku‐ku Japan
-
- Koichi Watashi
- Department of Virology II National Institute of Infectious Diseases Shinjuku‐ku Japan
-
- Tsuyoshi Shirai
- Faculty of Bioscience Nagahama Institute of Bio‐Science and Technology Japan
この論文をさがす
説明
<jats:p>Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti‐severe acute respiratory syndrome coronavirus 2 (anti‐SARS‐CoV‐2) activity. In this study, we evaluated whether natural analogues of CEP may act as potential anti‐coronavirus disease 2019 drugs. A total of 24 compounds resembling CEP were extracted from the KNApSAcK database, and their binding affinities to target proteins, including the spike protein and main protease of SARS‐CoV‐2, NPC1 and TPC2 in humans, were predicted via molecular docking simulations. Selected analogues were further evaluated by a cell‐based SARS‐CoV‐2 infection assay. In addition, the efficacies of CEP and its analogue tetrandrine were assessed. A comparison of the docking conformations of these compounds suggested that the diphenyl ester moiety of the molecules was a putative pharmacophore of the CEP analogues.</jats:p>
収録刊行物
-
- FEBS Open Bio
-
FEBS Open Bio 12 (1), 285-294, 2021-12-09
Wiley
- Tweet
キーワード
- QH301-705.5
- Coronavirus M Proteins
- Protein Conformation
- coronavirus
- Drug Evaluation, Preclinical
- Molecular Dynamics Simulation
- Antiviral Agents
- Benzylisoquinolines
- Chlorocebus aethiops
- Animals
- Humans
- Biology (General)
- natural drug
- Vero Cells
- Research Articles
- Stephania
- drug repurposing
- SARS-CoV-2
- SARS‐CoV
- COVID-19
- molecular docking
- Molecular Docking Simulation
- Plant Preparations
- Protein Binding
詳細情報 詳細情報について
-
- CRID
- 1360013168751942272
-
- ISSN
- 22115463
-
- PubMed
- 34850606
-
- Web Site
- https://onlinelibrary.wiley.com/doi/pdf/10.1002/2211-5463.13337
- https://onlinelibrary.wiley.com/doi/full-xml/10.1002/2211-5463.13337
- https://febs.onlinelibrary.wiley.com/doi/pdf/10.1002/2211-5463.13337
- https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/615b9b32be10746e0e922d92/original/evaluating-cepharanthine-analogues-as-natural-drugs-against-sars-co-v-2.pdf
-
- 資料種別
- journal article
-
- データソース種別
-
- Crossref
- KAKEN
- OpenAIRE